Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Respira Therapeutics, Inc.

respiratherapeutics.com ↗

Clinical Phase 2

Also known as Respira Therapeutics · 3 sources

Keywords: respiratory pulmonary arterial hypertension inhaled

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Sep 25, 2020 Trial start 2B: Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study source ↗
Jul 30, 2019 Trial start Phase 2: A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension source ↗
Jul 31, 2018 Trial start Phase 1: A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234 source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT04266197	Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study	2B	Completed	Sep 25, 2020	Nov 20, 2024 (actual)
NCT05343637	A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension	Phase 2	Completed	Jul 30, 2019	Jan 17, 2020 (actual)
NCT05567367	A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234	Phase 1	Completed	Jul 31, 2018	Dec 4, 2019 (actual)